Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Abstract Background Dyslipidemia represents a significant non-infectious comorbidity among people living with HIV. The aim of this study is to evaluate the impact on lipid profile of switches from an efavirenz (EFV) or protease inhibitor/ritonavir (PI/r)-based regimen to a rilpivirine (RPV) or a onc...

Full description

Bibliographic Details
Main Authors: Lucia Taramasso, Paola Tatarelli, Elena Ricci, Giordano Madeddu, Barbara Menzaghi, Nicola Squillace, Giuseppe Vittorio De Socio, Canio Martinelli, Roberto Gulminetti, Paolo Maggi, Giancarlo Orofino, Francesca Vichi, Antonio Di Biagio, Paolo Bonfanti, on behalf of CISAI Study Group
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Infectious Diseases
Subjects:
Dyslipidemia
Rilpivirine
Integrase inhibitors
Cholesterol
Framingham risk score
Online Access:http://link.springer.com/article/10.1186/s12879-018-3268-5

Internet

http://link.springer.com/article/10.1186/s12879-018-3268-5

Similar Items